Today: 11 November 2025
Subscribe
Browse Tag

Gene Editing

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

CRISPR Trial Halt Triggers Sell-Off Intellia’s stock was hammered on Monday after the biotech stunned investors with news of a clinical trial pause. Before the opening bell, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening in two late-stage trials of its in vivo CRISPR treatment nexiguran ziclumeran (NTLA-2001) due to a serious adverse event reuters.com. A patient in the Phase 3 MAGNITUDE study – which tests NTLA-2001 in transthyretin amyloidosis patients with cardiomyopathy (ATTR-CM) – experienced Grade 4 elevations in liver enzymes and bilirubin after receiving the one-time gene therapy reuters.com ca.investing.com. This met the trial’s pre-specified safety
27 October 2025
 ·  ·  ·  · 
CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

Stock Price Rollercoaster in 2025 CRISPR Therapeutics’ stock has been on a wild ride this year. As of midday October 27, CRSP hovered around $67 per share – off its highs but still up dramatically from early 2025 levels genengnews.com. Over the past six months, the stock jumped 83% (from about $38 in April to the mid-$70s by mid-October) genengnews.com. Just this month, shares spiked 5% in three days after the company reported positive gene-editing data in a new therapy, briefly topping $71 genengnews.com. Year-to-date, CRSP had nearly doubled as of early October ts2.tech, reflecting growing investor enthusiasm for gene-editing
27 October 2025
 ·  ·  ·  ·  ·  ·  · 
Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Stock Rallies on Technical Breakout Beam Therapeutics’ stock surged on Monday, Oct. 20, extending a strong upward streak. By mid-afternoon the share price hit $30.35, up 16.8% for the day finviz.com. This marked BEAM’s highest price since early 2024 and a dramatic rebound from its summer lows. Traders point to a bullish “golden cross” pattern on Beam’s chart – the stock’s 50-day moving average recently rose above its 200-day average finviz.com, a technical signal often seen as confirmation of a positive trend reversal. Zacks noted that BEAM had rallied ~6.8% over the prior four weeks leading into this golden-cross
20 October 2025
 ·  ·  ·  ·  · 
CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1 antitrypsin deficiency (AATD). The data – highlighted at the ESGCT conference – showed that a single dose of CTX460 delivered by lipid nanoparticles corrected the disease-causing mutation in >90% of liver cells and boosted functional AAT protein ~5-fold in animal models globenewswire.com. “The preclinical results demonstrate the potential of CTX460, developed using our novel SyNTase editing platform, to correct the mutation with precision and efficiency,” said CRISPR CMO
19 October 2025
 ·  ·  ·  ·  · 
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Background and Pipeline Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021 Intellia reported the first clinical proof that in-body CRISPR editing could work – a single injection dramatically lowered the disease protein (transthyretin) in ATTR amyloidosis patients ts2.tech. Today, the company’s focus is on curative gene edits in severe diseases. Its lead programs are NTLA-2001 (nexiguran ziclumeran) for transthyretin amyloidosis (ATTR) and NTLA-2002 (lonvoguran ziclumeran) for hereditary angioedema (HAE) ts2.tech ts2.tech. Both use CRISPR delivered via lipid nanoparticles to
9 October 2025
 ·  ·  ·  ·  · 
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Quick Facts (as of 8 Oct 2025) Recent Performance and News Phase 1 data fuels rally Intellia’s October rally was triggered by longer‑term Phase 1 results for nexiguran ziclumeran (nex‑z), an in‑vivo CRISPR therapy for transthyretin (ATTR) amyloidosis. A GlobeNewswire release (Sept 25 2025) reported that a single dose produced a rapid, deep and durable reduction of serum TTR levels—mean reduction 92 % at 24 months and 90 % at 36 months globenewswire.com. Patients also showed clinical improvements or stabilization of neuropathy and cardiac markers globenewswire.com, and safety findings were mostly mild infusion‑related events globenewswire.com. CEO John Leonard said the data “demonstrate rapid, deep and durable TTR reductions with meaningful clinical
8 October 2025
 ·  ·  ·  ·  · 
CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

Stock Price, Volume and Sentiment According to AAII, CRSP’s share price on 8 Oct 2025 closed at $77.727, up 10.06 % from the previous close. The stock traded between $70.77 and $78.38 that day and has risen ~20 % during October. Over the prior year the share price ranged from $30.04 to $73.95, and year‑to‑date performance stood at +97.5 %. Trading volume on INDmoney’s quote was 3.1 million shares indmoney.com. Fintel’s data as of 7 Oct 2025 list a market cap of roughly $6.2 billion, a beta of 1.32 and a short interest of 26.3 %, suggesting significant volatility and short‑seller interest fintel.io. The average one‑year price target of $81.3
8 October 2025
 ·  ·  ·  ·  · 
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia at a Glance: CRISPR Trailblazer in 2025 Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology company at the forefront of CRISPRgene editing medicines. Headquartered in Cambridge, MA, Intellia was one of the first companies to harness CRISPR-Cas9 technology to develop potential in vivo therapies – treatments delivered directly into the body to edit genes inside patients’ cells. In fact, Intellia reported the first-ever clinical evidence that CRISPR could provide a therapeutic benefit in humans via in-body gene editing, showing in 2021 that a one-time IV infusion could drastically lower a disease-causing protein in patients ts2.tech. This pioneering achievement, accomplished with their transthyretin amyloidosis (ATTR)
8 October 2025
 ·  ·  ·  ·  · 
Biting Back: How CRISPR-Edited Mice Could Stop the Lyme Disease Plague

Biting Back: How CRISPR-Edited Mice Could Stop the Lyme Disease Plague

Lyme Disease on the Rise – And Why Mice Matter Lyme disease is often called a “plague” on Nantucket. The tiny Massachusetts island, famed for its beaches, has one of the nation’s highest infection rates media.mit.edu. About 15% of Nantucket’s residents have contracted Lyme disease, which causes fevers, rashes, swollen joints, and even nerve damage cbsnews.com cbsnews.com. The culprit is a spiral-shaped bacteria (Borrelia burgdorferi) spread by black-legged ticks, commonly known as deer ticks. But while deer and ticks get most of the blame, scientists point to a different host at the heart of Lyme’s spread: the white-footed mouse cbsnews.com.
23 September 2025
 ·  ·  ·  · 
CRISPR ‘Prime Editing’ Breakthrough Cures Genetic Liver Disease in Mice

CRISPR ‘Prime Editing’ Breakthrough Cures Genetic Liver Disease in Mice

Breaking the Genetic “Spell” of a Liver Disease Phenylketonuria (PKU) is a hereditary metabolic liver disorder where a single DNA typo disrupts the PAH enzyme that breaks down phenylalanine, an amino acid nature.com fiercebiotech.com. Without a working PAH enzyme, phenylalanine builds up to toxic levels, causing brain damage, intellectual disability, and seizures if untreated. Newborn screening identifies PKU early, and patients are put on a strict lifetime diet limiting protein (to keep blood Phe 120–360 µM) pennmedicine.org fiercebiotech.com. Even with dietary control and medications, many patients struggle – foods high in protein are largely off-limits, and even newer drugs like
15 September 2025
 ·  ·  ·  · 
From a Gene-Edited Baby to Uranus’ Hidden Moon: August 2025’s Biggest Science Breakthroughs

From a Gene-Edited Baby to Uranus’ Hidden Moon: August 2025’s Biggest Science Breakthroughs

August 2025 was packed with scientific advances across health, space, physics, AI, environment, energy, biology, chemistry, and technology. Below we round up the most significant global science news of the month, with each section highlighting key developments and expert insights. Health & Medicine Space & Astronomy Physics Artificial Intelligence (AI is also accelerating drug discovery: in August, one team used AI to scan genomes of Archaea and identified new antimicrobial molecules effective against superbugs sci.news sci.news. This approach could vastly expand our library of antibiotic candidates, demonstrating AI’s growing role in biology and medicine.) Climate Science Environment & Ecology (In
21 August 2025
 ·  ·  ·  · 
Go toTop